U.S. markets closed
  • S&P Futures

    3,688.00
    -21.00 (-0.57%)
     
  • Dow Futures

    29,525.00
    -144.00 (-0.49%)
     
  • Nasdaq Futures

    11,315.00
    -61.75 (-0.54%)
     
  • Russell 2000 Futures

    1,675.80
    -10.30 (-0.61%)
     
  • Crude Oil

    78.99
    +0.25 (+0.32%)
     
  • Gold

    1,636.80
    -18.80 (-1.14%)
     
  • Silver

    18.52
    -0.39 (-2.04%)
     
  • EUR/USD

    0.9639
    -0.0049 (-0.51%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0569
    -0.0288 (-2.65%)
     
  • USD/JPY

    143.7010
    +0.3810 (+0.27%)
     
  • BTC-USD

    18,789.10
    -167.13 (-0.88%)
     
  • CMC Crypto 200

    431.05
    -13.48 (-3.03%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    26,580.10
    -573.73 (-2.11%)
     

Catalent, Inc. to Present at September Investor Conferences

·1 min read

SOMERSET, N.J., September 08, 2022--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at two upcoming investor conferences.

On September 13, 2022 at 11:45 a.m. ET, the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference.

On September 14, 2022, at 10:50 a.m. ET, the Company will present at Baird’s 2022 Global Healthcare Conference.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 19,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005773/en/

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com